Literature DB >> 17219465

Effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia.

Scott A Flanders1, Vicky Dudas, Kathleen Kerr, Charles E McCulloch, Ralph Gonzales.   

Abstract

BACKGROUND: Limited data exist on the effectiveness of ceftriaxone plus doxycycline in the treatment of patients hospitalized with community-acquired pneumonia (CAP).
METHODS: We performed a retrospective cohort study of all adults hospitalized for pneumonia between January 1999 and July 2001 at an academic medical center. Outcomes were compared for patients with CAP treated with ceftriaxone plus doxycycline versus other appropriate initial empiric antibiotic therapies. Outcomes were adjusted with the use of a propensity score to account for differences in patient characteristics and illness severity between groups.
RESULTS: A total of 216 patients were treated with ceftriaxone plus doxycycline and 125 received other appropriate initial empiric antibiotic therapies. After adjustment, use of ceftriaxone plus doxycycline was associated with reduced inpatient mortality (OR = 0.26, 95% CI: 0.08-0.81) and 30-day mortality (OR = 0.37, 95% CI: 0.17-0.81), but not with length of stay or readmission rates. Analysis of a subset of the sample that excluded patients admitted from nursing homes, patients admitted to the ICU, and patients diagnosed with aspiration also showed reduced inpatient mortality with the use of ceftriaxone plus doxycycline.
CONCLUSIONS: The use of ceftriaxone plus doxycycline as an initial empiric therapy for patients hospitalized with CAP appears safe and effective, and its potential superiority should be evaluated prospectively. (c) 2006 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17219465     DOI: 10.1002/jhm.8

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  4 in total

1.  Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia.

Authors:  Moe Uddin; Turab Mohammed; Mark Metersky; Antonio Anzueto; Carlos A Alvarez; Eric M Mortensen
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

2.  Ceftriaxone, an FDA-approved cephalosporin antibiotic, suppresses lung cancer growth by targeting Aurora B.

Authors:  Xiang Li; Haitao Li; Shengqing Li; Feng Zhu; Dong Joon Kim; Hua Xie; Yan Li; Janos Nadas; Naomi Oi; Tatyana A Zykova; Dong Hoon Yu; Mee-Hyun Lee; Myoung Ok Kim; Lei Wang; Weiya Ma; Ronald A Lubet; Ann M Bode; Ziming Dong; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-09-07       Impact factor: 4.944

Review 3.  Insights on production mechanism and industrial applications of renewable propylene glycol.

Authors:  Jude A Okolie
Journal:  iScience       Date:  2022-08-10

4.  Adherence to Treatment Guideline Improves Patient Outcomes in a Prospective Cohort of Adults Hospitalized for Community-Acquired Pneumonia.

Authors:  Grace Lui; Heather K W To; Nelson Lee; Renee W Y Chan; Timothy Li; Rity Y K Wong; David S C Hui; Margaret Ip
Journal:  Open Forum Infect Dis       Date:  2020-04-24       Impact factor: 3.835

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.